Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update Summary-Reference-Cited by-同舟云学术

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update Summary

Published:2017-12 Issue:12 Volume:13 Page:822-824
ISSN:1554-7477
Container-title:Journal of Oncology Practice
language:en
Short-container-title:JOP

Author:

Van Poznak Catherine¹,Somerfield Mark R.¹,Moy Beverly¹

Affiliation:

1. University of Michigan, Ann Arbor, MI; American Society of Clinical Oncology, Alexandria, VA; and Massachusetts General Hospital, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Health Policy,Oncology (nursing),Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JOP.2017.027672

Reference6 articles.

1. American Society of Clinical Oncology Clinical Practice Guideline Update: Recommendations on the Role of Bone-Modifying Agents in Metastatic Breast Cancer

2. American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer

3. American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast Cancer

4. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial

5. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects;Supportive Care in Cancer;2024-03

2. Correction of Electrolyte Abnormalities in Critically Ill Patients;Intensive Care Research;2024-01-22

3. The use of bone-modifying agents in multiple myeloma;Blood Reviews;2023-01

4. Bone Health in Metastatic Cancer;Seminars in Oncology Nursing;2022-04

5. It is time to prepare for D-CARE!;Annals of Translational Medicine;2020-11